Lakefront Biotherapeutics (LKFT) Gains from Investment Securities (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Gains from Investment Securities for 9 consecutive years, with $53.3 million the latest figure, recorded in Q1 2026.

• Quarterly Gains from Investment Securities rose 10.96% year-over-year to $53.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.3 million (up 10.96% YoY) and the FY2025 annual result came in at $54.3 million, up 12.45% from the prior year.
• Gains from Investment Securities slipped to $53.3 million in Q1 2026 per LKFT's latest filing, from $54.3 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for LKFT reached as high as $57.6 million in Q2 2025 and fell as low as $48.0 million in Q1 2025.
• A 3-year average of $51.8 million and a median of $50.9 million in 2026 frame the typical range for Gains from Investment Securities.
• The largest YoY upside for Gains from Investment Securities was 14.49% in 2025 against a maximum downside of 1.32% in 2025.
• Year by year, Gains from Investment Securities stood at $48.3 million in 2024, then gained by 12.45% to $54.3 million in 2025, then dropped by 2.0% to $53.3 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $53.3 million, $54.3 million, and $55.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.